SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Discussion centers on Midnights mainnet launch and reported Coinbase listing, with traders also highlighting Google Cloud and Vodafone validator participation as signs of growing reach. Supporters see adoption momentum, while skeptics point to ongoing token-selling pressure and question whether the developments will translate into sustained demand.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs planned acquisition of Grains 800 MHz spectrum has fueled concern that Starlink Mobile could eventually compete with T-Mobile and other wireless carriers. Traders are split between viewing the move as a long-term competitive threat and calling the selloff an overreaction, given the infrastructure needed to build a rival network and T-Mobiles pushback that spectrum alone does not make a network.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs sharp swings are driving the discussion, with traders pointing to a rally they associate with CME futures access and a Grayscale filing, followed by a pullback. Bulls see the moves and BCHs relative resilience as signs of strength, while skeptics question its utility and warn of further declines.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs rally and elevated trading volume are drawing attention as traders look ahead to Patrick Soon-Shiongs Piper Sandler fireside chat, where he is expected to discuss trial progress. The community also cites falling short interest and possible covering, while rumors of a partnership or other undisclosed news remain speculative.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances rally is being tied to its stronger commercial outlook and anticipation of upcoming melanoma and sarcoma presentations, earnings, and an NSCLC data update; traders also point to a reported decline in short interest as a possible tailwind. The community is broadly bullish on the catalysts, while some caution that the sharp run-up may bring profit-taking and that clinical results remain uncertain.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention amid weak price performance and concerns about exchange delistings, with traders debating whether the listing changes are materially bearish or being overstated. Bulls point to JasmyChain activity and ecosystem developments as potential sources of utility, while critics question whether meaningful adoption has emerged.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas proposed first U.S. data-center acquisition and broader AI-infrastructure expansion plan are driving discussion. Many traders welcome the strategic move, while skeptics focus on the non-binding nature of the deal, the lack of disclosed financing, and concerns about dilution and execution of existing projects.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is being linked to its Nasdaq-100 reentry, which prompted index-fund buying, and a reported NIH effort to accelerate personalized cancer vaccines; traders also cite optimism around the companys cancer-vaccine program. Bulls point to the pipeline and buying momentum, while skeptics argue the valuation has run ahead of fundamentals given ongoing losses and the uncertainty of future clinical and commercial results.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Traders are focused on the planned AerodromeVelodrome merger and expansion of the unified Aero protocol beyond Base to Ethereum and other chains, which they see as a potential source of broader liquidity and fee growth. Sentiment is largely bullish around a breakout toward the $1 level, though some question the rollout timing and warn that emissions or sell-the-news activity could weigh on the token.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

The DOJs clearance of Transoceans planned all-stock Valaris merger is a key focus, alongside new contract awards that add to backlog. Traders see potential synergies and elevated short interest as bullish, while others are frustrated by the muted share response and cite debt, dilution, and continued selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study Bristol Myers Squibb (NYSE: BMY) today...

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Key PointsJohnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption...

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

Bristol Myers Squibb (NYSE: BMY) today announced the expansion of Champions in Care, the company's initiative honoring healthcare professionals (HCPs), first launched in 2025. Now in its second year, the campaign builds on its inaugural effort that celebrated HCPs across therapeutic areas through...

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibbs CAMZYOS (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg...

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (NYSE: BMY) today announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) versus daratumumab, bortezomib, and...

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2026 on Thursday, October 29, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.Investors and the general public are invited to...

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Bristol Myers Squibb (NYSE: BMY) today announced positive results through two years of treatment from the Phase 3 POETYK PsA-2 study, including its open-label extension (OLE), showing durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic...

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on November 2, 2026, to stockholders of record at the close of business...

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel, in Patients with Quadruple-Class Exposed Relapsed and Refractory Multiple Myeloma Bristol Myers...

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Bristol Myers Squibb (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic...

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

CELG Celgene Corporation

Latest CELG News